Search for a command to run...
Hims & Hers Health, Inc.
Drug Manufacturers - Specialty & Generic
| Date | Politician | Asset | Action | Amount | Trade Price | 30D Price | 1M Return | Alpha | 1M Prediction |
|---|---|---|---|---|---|---|---|---|---|
Feb 3, 2026 |  Tony WiedR | Stock | Buy |
| $50,001 - $100,000 |
| $25.54 |
| $15.88 |
| -37.8% |
| -36.6% |
Dec 17, 2025 | Tony WiedR | Stock | Sell | $100,001 - $250,000 | $34.97 | $31.38 | -10.3% | -13.6% |
Aug 4, 2025 |  Lisa McClainR | Stock | Buy | $1,001 - $15,000 | $63.35 | $44.46 | -29.8% | -31.8% |
Feb 25, 2025 | Tony WiedR | Stock | Buy | $15,001 - $50,000 | $39.86 | $31.92 | -19.9% | -15.6% |
Feb 24, 2025 | Tony WiedR | Stock | Buy | $100,001 - $250,000 | $51.31 | $33.36 | -35.0% | -30.5% |
Regulatory Pressure Tests Novo Nordisk’s GLP 1 Moat And Valuation
Novo Nordisk Tests Wegovy Patent Strength As Compounded Rivals Face Scrutiny
Novo Nordisk opens new front with patent suit over Hims’ Wegovy copies
As Hims & Hers Gets Hit With Major Wegovy Loss, Should You Buy the Dip in Deeply Oversold HIMS Stock?
Hims & Hers says Novo Nordisk lawsuit ‘blatant attack’ on millions of Americans